title: [Quadrivalent HPV 6/11/16/18 vaccine].
abstract: This randomized, double-blind study included 12,167 women who received three doses of quadrivalent HPV 6/11/16/18 vaccine or placebo (day 1, month 2, and month 6). The participants were followed for an average of 3 years. The vaccine prevented 98% of CIN2, CIN3 and adenocarcinoma in situ related to HPV 16 or HPV 18 among women not previously exposed to these types, and 44% among all women (i.e. both those with and without previous infection). The vaccine efficacy against all high-grade cervical lesions, independent of causal HPV type, was estimated to 17%.
authors: Rigshospitalet, Juliane Marie Center, Kraeftens Bekaempelse, Institut for Epidemiologisk Kraeftforskning, Aalborg Sygehus. susanne@cancer.dk
authors: Susanne Krüger
authors: SK
authors: Kjaer
authors: Erik Søgård
authors: ES
authors: Andersen
authors: Henning
authors: H
authors: Djursing
authors: Tom
authors: T
authors: Hansen
authors: Jens Jørgen
authors: JJ
authors: Jørgensen
authors: Lisbeth
authors: L
authors: Nilas
authors: Bent S
authors: BS
authors: Ottesen
authors: Lone Keld
authors: LK
authors: Petersen
authors: Steen Grove
authors: SG
authors: Thomsen
authors: Kim
authors: K
authors: Toftager-Larsen